Navidea Biopharmaceuticals Inc

Type: Company
Name: Navidea Biopharmaceuticals Inc
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Commit To Purchase Navidea Biopharmaceuticals At $1, Earn 15.7% Annualized Using Options

Investors considering a purchase of Navidea Biopharmaceuticals, Inc. (NAVB) stock, but tentative about paying the going market price of $1.29/share, might benefit from considering selling puts among the alternative strategies at their disposal..Related ... [Published CEOWorld Magazine - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Navidea Biopharmaceuticals Short Interest Up 0.3% in August (NAVB)

Navidea Biopharmaceuticals (NYSE:NAVB) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 24,198,923 shares, a growth of 0.3% from the July 31st total of 24,116,182 shares, reports. ... [Published American Banking News - Aug 27 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Leading Small-Cap Stars Health Care Stock for August 6 Morning Session is Accelerate Diagnostics Inc (AXDX)

The world of small-cap health care investing is one of huge booms and major busts. However, equities.com's Small-Cap Stars, our proprietary list of small-cap companies with characteristics we've found to be most predictive of future success, helps you ... [Published 4 Traders - Aug 16 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 2 reports

Navidea Biopharmaceuticals Price Target Increased to $5.00 by Analysts at JMP Securities (NAVB)

Research analysts at JMP Securities lifted their price target on shares of Navidea Biopharmaceuticals (NASDAQ:NAVB) Navidea Biopharmaceuticals (NASDAQ:NAVB) opened at 1.30 on Thursday. Navidea Biopharmaceuticals has a 52-week low of $1.11 and a 52-week ... [Published American Banking News - Stock Ratings - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Leading Health Care Stock for Small-Cap Stars is ERBA Diagnostics (ERB) for July 31

Investing in small-cap health care companies can be tricky, with stocks that can soar or crash based on the results of a single clinical trial. However, equities.com's Small-Cap Stars, our proprietary list of small-cap companies with characteristics we've ... [Published 4 Traders - Aug 07 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 3 reports

Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million

DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea reported Q2 2014 financial results with revenue to Navidea from sales of Lymphoseek® growing to more than $1 million in Q2/2014 and reiterated revenue expectation of $5-6M for full-year 2014. ... [Published EON Science - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 2 reports

Navidea Biopharmaceuticals, Inc's (NAVB) CEO Michael Goldberg on Q2 2014 Results - Earnings Call Transcript

OperatorWelcome to the Navidea Biopharmaceuticals Second Quarter 2014 earnings call. My name is Larissa, and I'll be your operator for today's call. [Operator Instructions] Please note, this conference is being recorded. And I'd like to turn the call ... [Published Seeking Alpha - Aug 06 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceuticalcompany focused on precision diagnostic radiopharmaceuticals, todayannounced that the Company will report its financial results for thesecond quarter 2014, on Wednesday, August 6, 2014 ... [Published Street Sweeper - Jul 29 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 3 reports

Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014

DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 with a guest speaker, Dr. Stephen Lai. ... [Published EON Science - Jul 02 2014]
First reported Jun 13 2014 - Updated Jun 14 2014 - 4 reports

Navidea Biopharma shares fall after negative report on Lymphoseek

(Reuters) - Navidea Biopharmaceuticals Inc's shares fell as much as 17 percent on Friday after a negative report on TheStreet.com despite the company receiving expanded U.S. approval for its imaging agent. The U.S. Food and Drug Administratio... ... [Published Yahoo! Health News - Jun 13 2014]
First reported Jun 10 2014 - Updated Jun 11 2014 - 4 reports

Navidea reports Phase III trial results of lymphosee to treat solid tumors

Navidea Biopharmaceuticals has announced results from combined analyses of Phase 3 clinical trials that evaluated Lymphoseek efficacy in lymphatic mapping for identifying pathology-positive lymph nodes across multiple solid tumor types: melanoma, bre ... [Published BioPortfolio - Jun 11 2014]
First reported May 07 2014 - Updated May 07 2014 - 3 reports

Navidea Biopharmaceuticals Announces First Quarter 2014 Financial Results

DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea Biopharmaceuticals announced its financial results and business highlights for the first quarter of 2014. ... [Published EON Science - May 07 2014]

Quotes

Immanuel Thangaraj, Managing Director and Partner at Essex Woodlands and R-NAV Director, added, "A broad-based approach using radiopharmaceuticals would enable earlier detection and therapeutic intervention before irreversible damage occurs in joints, distinguish between autoimmune and degenerative diseases, and potentially improve patient outcomes and quality of care."
"Navidea intends to continue its investment in Lymphoseek to further expand its use in other types of cancer, where current alternatives are neither efficient nor effective" Goldberg said
Original Article: NEXT ARTICLE More From BioPortfolio on "FDA approves Navidea's Lymphoseek for expanded use in head and neck cancer patients"

More Content

All (139) | News (35) | Reports (0) | Blogs (99) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Constellation Energy Partners Llc (CEP) is Top ... [Published Equities.com - Aug 29 2014]
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - Aug 29 2014]
Commit To Purchase Navidea Biopharmaceuticals A... [Published CEOWorld Magazine - Aug 28 2014]
Navidea Biopharmaceuticals Short Interest Up 0.... [Published American Banking News - Aug 27 2014]
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Leading Small-Cap Stars Health Care Stock for A... [Published 4 Traders - Aug 16 2014]
Leading Small-Cap Stars Health Care Stock for A... [Published Equities.com - Aug 15 2014]
Navidea Biopharmaceuticals Price Target Increas... [Published American Banking News - Stock Ratings - Aug 07 2014]
Navidea Biopharmaceuticals (NAVB) Raised at JMP... [Published Wall Street Pit - Aug 07 2014]
Leading Health Care Stock for Small-Cap Stars i... [Published 4 Traders - Aug 07 2014]
Navidea Biopharmaceuticals, Inc's (NAVB) CEO Mi... [Published Seeking Alpha - Aug 06 2014]
Navidea Announces Second Quarter 2014 Financial... [Published Investor's Business Daily - Aug 06 2014]
Navidea Announces Second Quarter 2014 Financial... [Published EON Science - Aug 06 2014]
Navidea Announces Second Quarter 2014 Financial... [Published Business Wire Science: Science News - Aug 06 2014]
Navidea Announces Second Quarter 2014 Financial... [Published Business Wire Health News - Aug 06 2014]
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - Aug 01 2014]
NAVIDEA BIOPHARMACEUTICALS : Updates on 2014 An... [Published 4 Traders - Jul 30 2014]
Navidea Biopharmaceuticals to Announce Second Q... [Published Street Sweeper - Jul 29 2014]
Navidea Biopharmaceuticals to Announce Second Q... [Published Business Wire Health News - Jul 29 2014]
Navidea Partners with Essex Woodland's Rheumco ... [Published Pharmacy Choice - Jul 27 2014]
Navidea Biopharmaceuticals Announces 2014 Annua... [Published Business Wire Health News - Jul 17 2014]
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Navidea Joins Essex Woodland’s Rheumco to Devel... [Published Business Wire Health News - Jul 16 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published EON Science - Jul 02 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Science: Science News - Jul 02 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Health News - Jul 02 2014]
Navidea Biopharmaceuticals to Present at the 9t... [Published Business Wire Health News - Jun 17 2014]
Navidea's sNDA for Lymphoseek injection gets FD... [Published Pharmaceutical Technology - Jun 17 2014]
FDA approves Navidea's Lymphoseek for expanded ... [Published BioPortfolio - Jun 16 2014]
FDA approves Navidea's Lymphoseek for expanded ... [Published PBR - News - Jun 16 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Navidea Announces Second Quarter 2014 Financial... [Published EON Science - Aug 06 2014]
DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea reported Q2 2014 financial results with revenue to Navidea from sales of Lymphoseek® growing to more than $1 million in Q2/2014 and reiterated revenue expectation of $5-6M for full-year 2014. ...
Navidea Announces Second Quarter 2014 Financial... [Published Business Wire Science: Science News - Aug 06 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea reported Q2 2014 financial results with revenue to Navidea from sales of Lymphoseek® growing to more than $1 million in Q2/2014 and reiterated revenue expectation of $5-6M for full-year 2014. ...
Navidea Announces Second Quarter 2014 Financial... [Published Business Wire Health News - Aug 06 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea reported Q2 2014 financial results with revenue to Navidea from sales of Lymphoseek® growing to more than $1 million in Q2/2014 and reiterated revenue expectation of $5-6M for full-year 2014. ...
Navidea Biopharmaceuticals to Announce Second Q... [Published Business Wire Health News - Jul 29 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea will report its financial results for the second quarter 2014, on Wednesday, August 6, 2014 before the market opens followed by a conference call with the investment community at 8:30 AM EDT. ...
Navidea Biopharmaceuticals Announces 2014 Annua... [Published Business Wire Health News - Jul 17 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals announced the results of voting at its 2014 Annual Meeting of Stockholders (the Annual Meeting) held July 17, 2014. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Navidea Announces Restructuring of Pipeline Dev... [Published GlobeNewswire: Advertising News - May 15 2014]
Technical Data on Biotech Equities -- Research ... [Published Financial Services - May 14 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.